Polymeric nanostructure vaccines: applications and challenges

References

• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–1608.
   PubMed Web of Science ®Google Scholar
• Pasquale A, Preiss S, Silva F, et al. Vaccine Adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015;3(2):320–343.
   PubMed Web of Science ®Google Scholar
• Kedl RM, Seder R. Editorial overview: vaccines. Curr Opin Immunol. 2017;47:A1–A2.
   PubMed Web of Science ®Google Scholar
• González-Fernández Á, Faro J, Fernández C. Immune responses to polysaccharides: lessons from humans and mice. Vaccine. 2008;26(3):292–300.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Mauler R, Gruschkau H, et al. The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp Cell Biol. 1976;44(1):12–19.
   PubMedGoogle Scholar
• Edelman R. Vaccine Adjuvants. Clin Infect Dis. 1980;2(3):370–383.
   Google Scholar
• Scherr GH, Markowitz AS, Skelton LZ. A new alginate adjuvant. J Appl Bacteriol. 1965;28(1):174–180.
   Google Scholar
• Preis I, Langer RS. A single-step immunization by sustained antigen release. J Immunol Methods. 1979;28(1–2):193–197.
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Alpar HO, Brown MR. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J Pharm Pharmacol. 1993;45(3):198–203.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Roberts MJJ, et al. Controlled release microparticles for vaccine development. Vaccine. 1991;9(10):768–771.
   PubMed Web of Science ®Google Scholar
• Reid RH, Boedeker EC, McQueen CE, et al. Preclinical evaluation of microencapsulated CFA/II oral vaccine against enterotoxigenic. E Coli Vaccine. 1993;11(2):159–167.
   PubMed Web of Science ®Google Scholar
• Alonso MJ, Gupta RK, Min C, et al. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine. 1994;12(4):299–306.
   PubMed Web of Science ®Google Scholar
• Lambricht L, Peres C, Florindo H, et al. Polymer-based nanoparticles as modern vaccine delivery systems. In: Skwarczynski M, Toth I, editors. Micro and nanotechnology in vaccine development. New Yok (NY): William Andrew Publishing; 2017. p. 185–203.
   Google Scholar
• Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol Rev. 2007;219(1):143–156.
   PubMed Web of Science ®Google Scholar
• Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006;27(12):573–579.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Friedland LR, Hanon E, et al. Towards an evidence based approach for the development of adjuvanted vaccines. Curr Opin Immunol. 2017;47:93–102.
   PubMed Web of Science ®Google Scholar
• Shi S, Zhu H, Xia X, et al. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37(24):3167–3178.
   PubMed Web of Science ®Google Scholar
• Sharma R, Agrawal U, Mody N, et al. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities. Biotechnol Adv. 2015;33(1):64–79.
   PubMed Web of Science ®Google Scholar
• Halliday J. Commercial aspects of vaccine development. In: Skwarczynski M, Toth I, editors. Micro and nanotechnology in vaccine development. New Yor (NY): William Andrew Publishing; 2017. p. 411–421.
   Google Scholar
• O’Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines. 2003;2(2):269–283.
   PubMedGoogle Scholar
• Hanes J, Cleland JL, Langer R. New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev. 1997;28(1):97–119.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327–337.
   PubMed Web of Science ®Google Scholar
• Crecente-Campo J, Guerra-Varela J, Peleteiro M, et al. The size and composition of polymeric nanocapsules dictate their interaction with macrophages and biodistribution in zebrafish. J Control Release. 2019;308:98–108.
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–618.
   PubMed Web of Science ®Google Scholar
• Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095–1107.
   PubMed Web of Science ®Google Scholar
• Dacoba TG, Olivera A, Torres D, et al. Modulating the immune system through nanotechnology. Semin Immunol. 2017;34:78–102.
   PubMed Web of Science ®Google Scholar
• Al-Halifa S, Gauthier L, Arpin D, et al. Nanoparticle-based vaccines against respiratory viruses. Front Immunol. 2019;10(22). DOI:10.3389/fimmu.2019.00022
   PubMed Web of Science ®Google Scholar
• Nevagi RJ, Skwarczynski M, Toth I. Polymers for subunit vaccine delivery. Eur Polym J. 2019;114:397–410.
   Web of Science ®Google Scholar
• Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, et al. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010;13(1):106–112.
   PubMed Web of Science ®Google Scholar
• Gutjahr A, Phelip C, Coolen AL, et al., Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting. Vaccines (Basel). 2016; 4(4):34.
   PubMed Web of Science ®Google Scholar
• Pombo García K, Zarschler K, Barbaro L, et al. Zwitterionic-coated “stealth” nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small. 2014;10(13):2516–2529.
   PubMed Web of Science ®Google Scholar
• Raghuvanshi RS, Katare YK, Lalwani K, et al. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm. 2002;245(1–2):109–121.
   PubMed Web of Science ®Google Scholar
• Moyano DF, Goldsmith M, Solfiell DJ, et al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc. 2012;134(9):3965–3967.
   PubMed Web of Science ®Google Scholar
• Diaz B, Sanchez-Espinel C, Arruebo M, et al. Assessing methods for blood cell cytotoxic responses to inorganic nanoparticles and nanoparticle aggregates. Small. 2008;4(11):2025–2034.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–496.
   PubMed Web of Science ®Google Scholar
• Correia-Pinto JF, Peleteiro M, Csaba N, et al. Multi-enveloping of particulated antigens with biopolymers and immunostimulant polynucleotides. J Drug Deliv Sci Tec. 2015;30:424–434.
   Web of Science ®Google Scholar
• AbdelAllah NH, Gaber Y, Rashed ME, et al. Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice. Int J Biol Macromol. 2020;152:904–912.
   PubMed Web of Science ®Google Scholar
• Miura R, Sawada S-I, Mukai S-A, et al. Antigen delivery to antigen-presenting cells for adaptive immune response by self-assembled anionic polysaccharide nanogel vaccines. Biomacromolecules. 2020;21(2):621–629.
   PubMed Web of Science ®Google Scholar
• Li P, Wang F. Polysaccharides:candidates of promising vaccine adjuvants. Drug Discov Ther. 2015;9(2):88–93.
   PubMed Web of Science ®Google Scholar
• Sunasee R, Narain R. Carbohydrate nanotechnology applied to vaccine development. In: Stine KJ, editor. Carbohydrate nanotechnology. Hoboken, NJ: John Wiley & Sons, Inc; 2015. p. 369–385.
   Google Scholar
• Moran HBT, Turley JL, Andersson M, et al. Immunomodulatory properties of chitosan polymers. Biomaterials. 2018;184:1–9.
   PubMed Web of Science ®Google Scholar
• Farace C, Sánchez-Moreno P, Orecchioni M, et al. Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol. Sci Rep. 2016;6(1):18423.
   PubMed Web of Science ®Google Scholar
• Peleteiro M, Presas E, González-Aramundiz JV, et al. Polymeric nanocapsules for vaccine delivery: influence of the polymeric shell on the interaction with the immune system. Front Immunol. 2018;9:791.
   PubMed Web of Science ®Google Scholar
• Jayakumar R, Menon D, Manzoor K, et al. Biomedical applications of chitin and chitosan based nanomaterials—A short review. Carbohydr Polym. 2010;82(2):227–232.
   Web of Science ®Google Scholar
• Sadati SF, Jamali A, Abdoli A, et al. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model. Pathog Dis. 2018;76(8). DOI:10.1093/femspd/fty070.
   PubMed Web of Science ®Google Scholar
• Bento D, Jesus S, Lebre F, et al. chitosan plus compound 48/80: formulation and preliminary evaluation as a hepatitis B vaccine adjuvant. Pharmaceutics. 2019;11(2):72..
   PubMed Web of Science ®Google Scholar
• Vicente S, Peleteiro M, Díaz-Freitas B, et al. Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: A needle-free vaccination strategy. J Control Release. 2013;172(3):773–781.
   PubMed Web of Science ®Google Scholar
• Vasiliev YM. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Rev Vaccines. 2015;14(1):37–53.
   PubMed Web of Science ®Google Scholar
• Pereira P, Pedrosa SS, Correia A, et al. Biocompatibility of a self-assembled glycol chitosan nanogel. Toxicol Vitro. 2015;29(3):638–646.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Aoshi T, Haseda Y, et al. Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines. EBioMedicine. 2017;15:127–136.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Cooper PD. Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine. 2015;33(44):5920–5926.
   PubMed Web of Science ®Google Scholar
• Kerlin RL, Watson DL. Effect of dextran sulphate on IgG subclass of antibody in efferent popliteal lymph of sheep. Immunol Cell Biol. 1987;65(5):411–417.
   PubMed Web of Science ®Google Scholar
• McCarthy RE, Arnold LW, Babcock GF. Dextran sulphate: an adjuvant for cell-mediated immune responses. Immunology. 1977;32(6):963–974.
   PubMed Web of Science ®Google Scholar
• Dieleman LA, Palmen MJHJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114(3):385–391.
   PubMed Web of Science ®Google Scholar
• Hyoung Park J, Sin Lim M, Rang Woo J, et al. The molecular weight and concentration of dextran sulfate affect cell growth and antibody production in CHO cell cultures. Biotechnol Prog. 2016;32(5):1113–1122.
   PubMed Web of Science ®Google Scholar
• Babcock GF, McCarthy RE. Suppression of cell-mediated immune responses by dextran sulphate. Immunology. 1977;33(6):925–929.
   PubMed Web of Science ®Google Scholar
• Yang F, Wang D, Li Y, et al. Th1/Th2 balance and Th17/Treg-mediated immunity in relation to murine resistance to dextran sulfate-induced colitis. J Immunol Res. 2017;2017:7047201.
   PubMed Web of Science ®Google Scholar
• Otterlei M, Østgaard K, Skjåk-Bræk G, et al. Induction of cytokine production from human monocytes stimulated with alginate. J Immunother. 1991;10(4):286–291.
   PubMed Web of Science ®Google Scholar
• Flo TH, Ryan L, Latz E, et al. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem. 2002;277(38):35489–35495.
   PubMed Web of Science ®Google Scholar
• Yang D, Jones KS. Effect of alginate on innate immune activation of macrophages. J Biomed Mat Res A. 2009;90A(2):411–418.
   Web of Science ®Google Scholar
• Dhamecha D, Movsas R, Sano U, et al. Applications of alginate microspheres in therapeutics delivery and cell culture: past, present and future. Int J Pharm. 2019;569:118627.
   PubMed Web of Science ®Google Scholar
• Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release. 2010;141(1):2–12.
   PubMed Web of Science ®Google Scholar
• Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195(1):99–111.
   PubMed Web of Science ®Google Scholar
• Gariboldi S, Palazzo M, Zanobbio L, et al. Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. J Immunol. 2008;181(3):2103–2110.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Yuba E, Hayashi H, et al. Development of pH-responsive hyaluronic acid-based antigen carriers for induction of antigen-specific cellular immune responses. ACS Biomater Sci Eng. 2019;5(11):5790–5797.
   PubMed Web of Science ®Google Scholar
• Nochi T, Yuki Y, Takahashi H, et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater. 2010;9(7):572–578.
   PubMed Web of Science ®Google Scholar
• DeFrates K, Markiewicz T, Gallo P, et al. Protein polymer-based nanoparticles: fabrication and medical applications. Int J Mol Sci. 2018;19(6):1717.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines. 2007;6(3):401–418.
   PubMed Web of Science ®Google Scholar
• Hoogenboezem EN, Duvall CL. Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev. 2018;130:73–89.
   PubMed Web of Science ®Google Scholar
• Zhu G, Lynn GM, Jacobson O, et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017;8(1):1954.
   PubMed Web of Science ®Google Scholar
• Momin N, Mehta NK, Bennett NR, et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med. 2019;11(498):eaaw2614.
   PubMed Web of Science ®Google Scholar
• He J, Zheng R, Zhang Z, et al. Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells. OncoImmunology. 2017;6(12):e1361094.
   PubMed Web of Science ®Google Scholar
• Sahoo N, Sahoo RK, Biswas N, et al. Recent advancement of gelatin nanoparticles in drug and vaccine delivery. Int J Biol Macromol. 2015;81:317–331.
   PubMed Web of Science ®Google Scholar
• Coester C, Nayyar P, Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. Eur J Pharm Biopharm. 2006;62(3):306–314.
   PubMed Web of Science ®Google Scholar
• Sudheesh MS, Vyas SP, Kohli DV. Nanoparticle-based immunopotentiation via tetanus toxoid-loaded gelatin and aminated gelatin nanoparticles. Drug Deliv. 2011;18(5):320–330.
   PubMed Web of Science ®Google Scholar
• Johansen P, Men Y, Audran R, et al. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res. 1998;15(7):1103–1110.
   PubMed Web of Science ®Google Scholar
• Offit PA, Jew RK. Addressing parents’ concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003;112(6 Pt 1):1394–1397.
   PubMed Web of Science ®Google Scholar
• Todd CW, Pozzi LAM, Guarnaccia JR, et al. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine. 1997;15(5):564–570.
   PubMed Web of Science ®Google Scholar
• Katz JM, Lu X, Todd CW, et al. A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine. 2000;18(21):2177–2187.
   PubMed Web of Science ®Google Scholar
• Mutwiri G, Benjamin P, Soita H, et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine. 2007;25(7):1204–1213.
   PubMed Web of Science ®Google Scholar
• Hsu WH, Csaba N, Alexander C, et al. Polyphosphazenes for the delivery of biopharmaceuticals. J Appl Polym Sci. 2020;137(25):48688.
   Google Scholar
• Cordeiro AS, Alonso MJ. Recent advances in vaccine delivery. Pharm Pat Anal. 2016;5(1):49–73.
   PubMed Web of Science ®Google Scholar
• Yoo JW, Irvine DJ, Discher DE, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10(7):521–535.
   PubMed Web of Science ®Google Scholar
• Trimaille T, Lacroix C, Verrier B. Self-assembled amphiphilic copolymers as dual delivery system for immunotherapy. Eur J Pharm Biopharm. 2019;142:232–239.
   PubMed Web of Science ®Google Scholar
• Ferreira SA, Gama FM, Vilanova M. Polymeric nanogels as vaccine delivery systems. Nanomed.-Nanotechnol. 2013;9(2):159–173.
   PubMed Web of Science ®Google Scholar
• Evelyn Roopngam P. Liposome and polymer-based nanomaterials for vaccine applications. Nanomed J. 2019;6(1):1–10.
   Google Scholar
• Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biological Chemistry. 2008;389(5):521–536.
   PubMed Web of Science ®Google Scholar
• Yang G, Chen S, Zhang J. Bioinspired and biomimetic nanotherapies for the treatment of infectious diseases. Front Pharmacol. 2019;10:751.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–517.
   PubMed Web of Science ®Google Scholar
• Larché M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med. 2005;11(4):S69–S76.
   PubMed Web of Science ®Google Scholar
• Thomas S, Prendergast GC. Cancer vaccines: a brief overview. In: Thomas S, editor. Vaccine design: methods and protocols: volume 1: vaccines for human diseases. New York: Springer New York; 2016. p. 755–761.
   Google Scholar
• Bonam SR, Partidos CD, Halmuthur SKM, et al. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017;38(9):771–793.
   PubMed Web of Science ®Google Scholar
• Deering RP, Kommareddy S, Ulmer JB, et al. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv. 2014;11(6):885–899.
   PubMed Web of Science ®Google Scholar
• Yang J, Li Y, Jin S, et al. Engineered biomaterials for development of nucleic acid vaccines. Biomater Res. 2015;19(1):5.
   PubMedGoogle Scholar
• Iavarone C, O’hagan DT, Yu D, et al. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017;16(9):871–881.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Javanzad S, Saleh T, et al. Polymeric nanoparticles. Hum Vaccin Immunother. 2014;10(2):321–332.
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Wei C-J, Yassine HM, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499(7456):102-6.
   PubMed Web of Science ®Google Scholar
• August A, Glenn GM, Kpamegan E, et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017;35(30):3749-59.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Fernandes JF, Bache EB, et al. Clinical development of RTS, S/AS malaria vaccine: a systematic review of clinical Phase I–III trials. Future Microbiology. 2015;10(10):1553-78.
   PubMed Web of Science ®Google Scholar
• Cech PG, Aebi T, Abdallah MS, et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One. 2011;6(7).
   Google Scholar
• Spearman P, Lally MA, Elizaga M, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J. Infect. Dis. 2011;203(8):1165-73.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Aderem AA. 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011;473(7348):463–469.
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LAB, Latz E, et al., Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098–aaf1098.
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, et al. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315–322.
   PubMed Web of Science ®Google Scholar
• Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol. 2009;9(1):15–27.
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6(2):148–158.
   PubMed Web of Science ®Google Scholar
• Shakya AK, Chowdhury MYE, Tao W, et al. Mucosal vaccine delivery: current state and a pediatric perspective. J Control Release. 2016;240:394–413.
   PubMed Web of Science ®Google Scholar
• Siegrist C-A. 2 - Vaccine immunology. In: Offit PA, Plotkin SA, Orenstein WA, editors. Vaccines (Sixth edition). London: W.B. Saunders; 2013. p. 14–32.
   Google Scholar
• Joffre OP, Segura E, Savina A, et al. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–569.
   PubMed Web of Science ®Google Scholar
• Arruebo M, Vilaboa N, Sáez-Gutierrez B, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2011;3(3):3279–3330..
   PubMedGoogle Scholar
• Seliger B. Combinatorial approaches with checkpoint inhibitors to enhance anti-tumor immunity. Front Immunol. 2019;10:999.
   PubMed Web of Science ®Google Scholar
• Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retrov. 1997;13(11):945–952.
   PubMed Web of Science ®Google Scholar
• Madani F, Hsein H, Busignies V, et al. An overview on dosage forms and formulation strategies for vaccines and antibodies oral delivery. Pharm Dev Technol. 2020;25(2):133–148.
   PubMed Web of Science ®Google Scholar
• Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol. 1987;7(4):265–276.
   PubMed Web of Science ®Google Scholar
• Mousavi T, Sattari Saravi S, Valadan R, et al. Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review. Arch Virol. 2020;165(2):263–284..
   PubMed Web of Science ®Google Scholar
• Zolnik BS, González-Fernández Á, Sadrieh N, et al. Minireview: nanoparticles and the immune system. Endocrinology. 2010;151(2):458–465.
   PubMed Web of Science ®Google Scholar
• Sainz V, Conniot J, Matos AI, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468(3):504–510.
   PubMed Web of Science ®Google Scholar
• Farjadian F, Ghasemi A, Gohari O, et al. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine. 2019;14(1):93–126.
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Cheng H-F, Yang Y-C, et al. Nanotechnologies applied in biomedical vaccines. In: Stanciu SG, editor. Micro and nanotechnologies for biotechnology. Croatia: InTech; 2016. p. 85–106.
   Google Scholar
• Zhao Q, Li S, Yu H, et al. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013;31(11):654–663.
   PubMed Web of Science ®Google Scholar
• López-Sagaseta J, Malito E, Rappuoli R, et al. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J. 2016;14:58–68.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, et al. Major findings and recent advances in virus–like particle (VLP)-based vaccines. Semin Immunol. 2017;34:123–132.
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Trocio J, Whitman L, et al., DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol. 2005; 124(1):160–169.
   PubMed Web of Science ®Google Scholar
• Pittet L, Altreuter D, Ilyinskii P, et al. Development and preclinical evaluation of SEL-068, a novel targeted synthetic vaccine particle (tSVP™) for smoking cessation and relapse prevention that generates high titers of antibodies against nicotine (75.11). J Immunol. 2012;188(1 Supplement):75. 11.
   Google Scholar
• Jiang W, Gupta RK, Deshpande MC, et al. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57(3):391–410.
   PubMed Web of Science ®Google Scholar
• Wischke C, Zimmermann J, Wessinger B, et al. Poly (I: C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm. 2009;365(1–2):61–68.
   PubMed Web of Science ®Google Scholar
• Silva AL, Soema PC, Slütter B, et al. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum Vaccin Immunother. 2016;12(4):1056–1069.
   PubMed Web of Science ®Google Scholar
• Malik A, Gupta M, Mani R, et al. Single-dose Ag85b-ESAT6–loaded poly(Lactic-co-glycolic acid) nanoparticles confer protective immunity against tuberculosis. Int J Nanomedicine. 2019;14:3129–3143.
   PubMed Web of Science ®Google Scholar
• Riitho V, Walters AA, Somavarapu S, et al. Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens. Sci Rep. 2017;7(1):1–10.
   PubMed Web of Science ®Google Scholar
• Moon JJ, Suh H, Polhemus ME, et al. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a plasmodium vivax malaria vaccine. PLoS ONE. 2012;7(2):e31472.
   PubMed Web of Science ®Google Scholar
• Vicente S, Diaz-Freitas B, Peleteiro M, et al. A polymer/oil based nanovaccine as a single-dose immunization approach. PLoS ONE. 2013;8(4):e62500.
   PubMed Web of Science ®Google Scholar
• Garcia-Fuentes M, Alonso MJ. Chitosan-based drug nanocarriers: where do we stand? J Control Release. 2012;161(2):496–504.
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen J, Zhou S, et al. Mouse IP-10 gene delivered by folate-modified chitosan nanoparticles and dendritic/tumor cells fusion vaccine effectively inhibit the growth of hepatocellular carcinoma in mice. Theranostics. 2017;7(7):1942–1952..
   PubMed Web of Science ®Google Scholar
• Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224.
   PubMed Web of Science ®Google Scholar
• Chahal JS, Khan OF, Cooper CL, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A. 2016;113(29):E4133–E4142.
   PubMed Web of Science ®Google Scholar
• Blanco E, Guerra B, De La Torre BG, et al. Full protection of swine against foot-and-mouth disease by a bivalent B-cell epitope dendrimer peptide. Antiviral Res. 2016;129:74–80.
   PubMed Web of Science ®Google Scholar
• Hegde N, Velingkar V, Prabhakar B. An update on design and pharmacology of dendritic poly(l-lysine). Int J Pept Res Ther. 2019;25(4):1539–1562.
   Web of Science ®Google Scholar
• Trimaille T, Verrier B. Micelle-based adjuvants for subunit vaccine delivery. Vaccines (Basel). 2015;3(4):803–813.
   PubMed Web of Science ®Google Scholar
• Luo Z, Wang C, Yi H, et al. Nanovaccine loaded with poly I: C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo. Biomaterials. 2015;38:50–60.
   PubMed Web of Science ®Google Scholar
• Florindo HF, Lopes J, Silva LC, et al. Regulatory development of nanotechnology-based vaccines. In: Skwarczynski M, Toth I, editors. Micro and nanotechnology in vaccine development. New York (NY): William Andrew Publishing; 2017. p. 393–410.
   Google Scholar
• Havel H, Finch G, Strode P, et al. Nanomedicines: from bench to bedside and beyond. AAPS J. 2016;18(6):1373–1378.
   PubMed Web of Science ®Google Scholar
• Kelly HG, Kent SJ, Wheatley AK. Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Rev Vaccines. 2019;18(3):269–280.
   PubMed Web of Science ®Google Scholar
• Wen R, Umeano AC, Kou Y, et al. Nanoparticle systems for cancer vaccine. Nanomedicine. 2019;14(5):627–648.
   PubMed Web of Science ®Google Scholar